文献速递临床试验与 GCP流行病学与生物统计

埃塞俄比亚中度急性营养不良脂质营养补充方案比较:MODAM-MAM随机对照试验

Comparative effectiveness of lipid-nutrient spread supplementation regimens for moderate acute malnutrition in Ethiopia: The MODAM-MAM individually randomized controlled trial.
PubMed 文献 · PLoS Med · 2026-08-11

该三臂平行个体随机对照试验纳入2414名6-59月龄中度急性营养不良儿童,比较每日1袋RUSF(标准)、1袋RUTF或2袋RUTF的补充效果。1-RUTF和2-RUTF在恢复率上均非劣于1-RUSF,2-RUTF恢复率略高但产品用量增加1.6倍,边际获益不足以抵消资源需求。

要点

  • 每日1袋RUTF或2袋RUTF在恢复率上均非劣于每日1袋RUSF标准方案。
  • 2-RUTF恢复率略高(88.1% vs 84.8%),但产品用量增加1.6倍,边际获益有限。
  • 1-RUTF与1-RUSF疗效相似,产品选择可依据供应、成本和操作因素决定。

核心结论

  • 每日1袋RUTF和每日2袋RUTF对中度急性营养不良的补充效果均非劣于每日1袋RUSF标准方案。
  • 2-RUTF恢复率略高但资源需求显著增加,边际获益不足以证明其合理性。
  • 1-RUTF与1-RUSF疗效相似,两者均可作为有效补充选项。

研究设计与样本

  • 在埃塞俄比亚开展的三臂、平行、个体随机对照试验。
  • 纳入6-59月龄中度急性营养不良儿童(MUAC 11.5-12.4 cm或WHZ -3至-2,无水肿)。
  • 随机分为每日1袋540 kcal RUSF、每日1袋500 kcal RUTF或每日2袋RUTF。
  • 采用预设6个百分点非劣效界值,主要结局为16周内连续两次访视MUAC≥12.5 cm且WHZ≥-2。
  • 意向性分析共纳入2414名儿童。

主要发现

  • 恢复比例:1-RUSF组84.8%(679/801),1-RUTF组85.0%(674/793),2-RUTF组88.1%(721/818)。
  • 相对1-RUSF的恢复风险差:1-RUTF为+0.2个百分点(95% CI [-3.3, 3.7];p=0.944)。
  • 2-RUTF相对1-RUSF的风险差为+3.4个百分点(95% CI [0.0, 6.7];p=0.050),两干预组均满足非劣效标准。
  • 体格增长和住院时间中位数(56天)各组相似。
  • 1-RUSF与1-RUTF产品用量相当,2-RUTF所需产品量为1.6倍。

关键数值与推荐

  • 非劣效界值为预设的6个百分点。
  • 主要结局定义为连续两次访视MUAC≥12.5 cm且WHZ≥-2,且在16周内。
  • 中度急性营养不良入组标准:MUAC 11.5-12.4 cm或WHZ在-3至-2之间,无水肿。

临床怎么用

  • 每日1袋RUTF或每日1袋RUSF均可作为中度急性营养不良儿童的有效补充方案。
  • 产品选择可依据供应、成本和操作可行性决定。
  • 每日2袋RUTF虽恢复率略高,但产品用量增加1.6倍,需权衡资源投入。

局限性

  • 仅评估了一种RUSF配方。
  • 因强化筛查导致病例发现早于常规情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate acute malnutrition (MAM), affecting over 30 million children globally, substantially increases the risk of morbidity and mortality. In 2023, the World Health Organization recommended lipid-based nutrient supplements (LNS) for children requiring supplementation for MAM, either ready-to-use supplementary food (RUSF) or ready-to-use therapeutic food (RUTF). However, evidence on the optimal product (RUTF or RUSF) and dosing strategy for children with MAM remains limited. The Modified Dosages for Acute Malnutrition MAM (MODAM-MAM) trial evaluated whether one- or two-sachet daily RUTF dosing were non-inferior to the de facto standard of one RUSF sachet daily for MAM supplementation. METHODS AND FINDINGS: We conducted a three-arm, parallel, individually randomized controlled trial in Ethiopia. Children aged 6-59 months with MAM (mid-upper arm circumference (MUAC) 11.5-12.4 cm or WHZ between -3 and -2, without edema) were randomized to: one 540-kcal sachet of RUSF/day ("1-RUSF"), one 500-kcal sachet of RUTF/day ("1-RUTF"), or two sachets of RUTF/day ("2-RUTF"). Both intervention arms (1-RUTF and 2-RUTF) were evaluated for non-inferiority to the standard (1-RUSF) using a prespecified 6-percentage-point margin. The primary outcome was anthropometric recovery, defined as both MUAC ≥ 12.5 cm and WHZ ≥ -2 for two consecutive visits within 16 weeks. In total, 2,414 children were analyzed in the intention-to-treat analysis. Recovery proportions were 84.8% (679/801) for 1-RUSF, 85.0% (674/793) for 1-RUTF, and 88.1% (721/818) for 2-RUTF. Risk differences for recovery relative to the standard of care (1-RUSF) were +0.2 percentage points (95% CI [-3.3, 3.7]; p = 0.944) for 1-RUTF and +3.4 percentage points (95% CI [0.0, 6.7]; p = 0.050) for 2-RUTF, with both intervention arms meeting the non-inferiority criteria. Anthropometric gains and median length of stay (56 days) were similar across arms. Ration use was comparable for 1-RUSF and 1-RUTF, while 2-RUTF required 1.6-fold more product. Study limitations include evaluation of a single RUSF formulation and earlier-than-typical case-finding due to intensive screening. CONCLUSIONS: Both experimental arms, one RUTF sachet daily and two RUTF sachets daily, are non-inferior to the standard dosing of one RUSF sachet daily for MAM supplementation. Although two sachets of RUTF daily yielded slightly higher recovery, the marginal benefits do not justify substantially greater resource demands. Because one RUTF and one RUSF sachet daily yielded similar treatment outcomes, either product can be considered an effective option for supplementation. Product choice may therefore be guided by supply, cost, and operational considerations. TRIAL REGISTRATION: clinicaltrials.gov NCT06056089.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Clark BA, Legese LA, Beyene Y, et al. Comparative effectiveness of lipid-nutrient spread supplementation regimens for moderate acute malnutrition in Ethiopia: The MODAM-MAM individually randomized controlled trial. PLoS Med. 2026. PMID: 42579725. doi:10.1371/journal.pmed.1005199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。